Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all

Roland P Kuiper, Patricia G Hoogeveen, Reno Bladergroen, Freerk van Dijk, Edwin Sonneveld, Frank N van Leeuwen, Judith Boer, Irina Sergeeva, Harma Feitsma, Monique L den Boer

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

Originele taal-2Engels
Pagina's (van-tot)888-892
Aantal pagina's5
TijdschriftBritish journal of haematology
Volume194
Nummer van het tijdschrift5
DOI's
StatusGepubliceerd - sep. 2021

Vingerafdruk

Duik in de onderzoeksthema's van 'Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all'. Samen vormen ze een unieke vingerafdruk.

Citeer dit